Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC
Author:
Affiliation:
1. Medical Oncology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Funder
no funding
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1903322
Reference61 articles.
1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
3. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid;Journal of Pharmaceutical and Biomedical Analysis;2024-08
2. Regulatory mechanisms of PD-1/PD-L1 in cancers;Molecular Cancer;2024-05-18
3. Current status and challenges of immunotherapy in ALK rearranged NSCLC;Frontiers in Oncology;2022-12-14
4. Progress in Treatment of Non-Small Cell Lung Cancer;Advances in Clinical Medicine;2022
5. A case of haemoptysis and bilateral areas of lung consolidation sparing the right lower lobe;Breathe;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3